[March 25, 2015]

Research and Markets: Hyperphosphatemia Pipeline Review, H1 2015 - 10 Companies & 16 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/5dktpx/hyperphosphatemia) has announced the addition of the "Hyperphosphatemia - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Hyperphosphatemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperphosphatemia ad special features on late-stage and discontinued projects.

The report enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MoAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• Astellas Pharma Inc.
• AstraZeneca plc
• Medice Arzneimittel Putter GmbH & Co. KG
• Mitsubishi (News - Alert) Tanabe Pharma Corporation
• OPKO Health, Inc.
• Panion & BF Biotech Inc.
• Sanofi
• Spectrum (News - Alert) Pharmaceuticals Inc.
• Toray Industries Inc.
• Vifor Pharma AG

Drug Profiles

• ASP-3325
• colestilan chloride
• Fe-SAMMS
• fermagate
• ferric citrate
• JPH-101
• niacinamide
• PT-20
• RDX-002
• Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia in CKD
• SPI-014
• sucroferric oxyhydroxide
• tenapanor hydrochloride
• TRK-390
• VS-501
• VS-505

For more information visit http://www.researchandmarkets.com/research/5dktpx/hyperphosphatemia.

[ Back To TMCnet.com's Homepage ]